For all these reasons, the development of GPBAR1 agonists represents an intriguing strategy for the treatment of metabolic disorders like type II diabetes, obesity, inflammatory diseases and some types of cancer9,19,20. The gene discussed is GPBAR1; the disease is obesity due to melanocortin 4 receptor deficiency.